An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies.
- Spencer, Andrew (Primary Chief Investigator (PCI))
- Kennedy, Nola (Project Manager)
Project: Research